Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T39608 |
Cirtuvivint
SM08502 |
CDK | Cell Cycle/Checkpoint |
Cirtuvivint (SM08502) 是一种有效且具有口服活性的 CDC 样激酶 (CLK) 抑制剂,可用于研究关节炎。 | |||
T36684 | Ipivivint | ||
Ipivivint, a first-in-class, orally active and potent CDC-like kinase (CLK) inhibitor, inhibits CLK1 (IC50=1.4 μM), CLK2 (IC50=0.002 μM) and CLK3 (IC50=0.022 μM). Ipivivint reduces Wnt pathway signaling gene expression through inhibiting CLK activity and serine and arginine rich splicing factor (SRSF) phosphorylation and disrupting spliceosome activity. Ipivivint can be used for the research of cancer[1]. Ipivivint (SW480 cells; 0.01~10 μM; 1 hour) potently inhibits SRSF5/6 phosphorylation[1].Ip... |